查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1298240

暈動病治療市場：按藥物類別、給藥途徑和分銷渠道：2021-2031 年全球機會分析和行業預測

Motion Sickness Treatment Market By Drug Class, By Route of Administration, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 263 Pages | 商品交期: 2-3個工作天內

價格

2021年暈車藥市場規模為3.937億美元，2022年至2031年復合年增長率為2.9%，2031年為52.503億美元，預計將達到1000萬美元。

暈動病，也稱為旅行病或暈動病，是一種以人在運動或鍛煉時出現的一系列症狀為特徵的疾病。 當眼睛、內耳和身體向大腦傳遞的感覺信息發生衝突時，就會發生暈動病。 大腦從眼睛和內耳接收到關於身體運動和方向的相互矛盾的信息，導致噁心、嘔吐、頭暈、頭痛、出汗和疲勞等症狀。 暈動病是由多種形式的運動引起的，例如乘車、飛行、劃船或體驗虛擬現實。

暈動病治療市場-IMG1

暈動病更容易發生在容易暈動病的人群中，例如兒童、孕婦和有偏頭痛病史的人。 暈動病的治療包括非處方藥和處方藥，例如抗組胺藥和抗膽鹼能藥。 推動暈車藥物市場增長的主要因素是暈車事件數量的增加以及公眾對暈車及其治療方案的認識不斷提高。

內容

第一章簡介

第 2 章執行摘要

第三章市場概述

  • 市場定義和範圍
  • 主要發現
    • 影響因素
    • 主要投資機會
  • 波特五力分析
    • 供應商的議價能力
    • 買家的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭強度
  • 市場動態
    • 協調員
      • 暈動病增加
      • 暈車藥物的迅速採用
      • 產品批准和產品發布激增：主要公司
    • 機會因素
      • 是否存在暈車療法的替代解決方案
      • 缺乏對暈車的認識和了解
    • 機會
      • 新興市場的增長機會
  • COVID-19 對市場的影響分析

第 4 章。暈動病藥物市場：按藥物類別

  • 概述
    • 市場規模和預測
  • 抗組胺藥
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 抗膽鹼能藥
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第 5 章。暈動病藥物市場：按給藥途徑

  • 概述
    • 市場規模和預測
  • 口頭
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第 6 章：暈車藥市場：按分銷渠道劃分

  • 概述
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 藥店和零售藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分
  • 網上藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區劃分
    • 市場份額分析：按國家/地區劃分

第 7 章。暈車藥市場：按地區

  • 概述
    • 市場規模/預測：按地區劃分
  • 北美
    • 主要趨勢和機遇
    • 市場規模和預測：按藥物類別劃分
    • 市場規模和預測：按管理途徑劃分
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家/地區劃分
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
  • 歐洲
    • 主要趨勢和機遇
    • 市場規模和預測：按治療類別劃分
    • 市場規模和預測：按管理途徑劃分
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家/地區劃分
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 歐洲其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
  • 亞太地區
    • 主要趨勢和機遇
    • 市場規模和預測：按治療類別劃分
    • 市場規模和預測：按管理途徑劃分
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家/地區劃分
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 亞太地區其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機遇
    • 市場規模和預測：按治療類別劃分
    • 市場規模和預測：按管理途徑劃分
    • 市場規模和預測：按分銷渠道劃分
    • 市場規模/預測：按國家/地區劃分
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分
      • 其他地區
      • 主要市場趨勢、增長動力和機遇
      • 市場規模和預測：按治療類別劃分
      • 市場規模和預測：按管理途徑劃分
      • 市場規模和預測：按分銷渠道劃分

第 8 章競爭格局

  • 簡介
  • 關鍵成功策略
  • 10家主要公司的產品圖譜
  • 競賽儀表板
  • 比賽熱圖
  • 2021 年頂級公司定位

第 9 章公司簡介

  • Prestige Consumer Healthcare Inc.
  • Baxter International Inc.
  • Novartis AG
  • WellSpring Pharmaceutical Corporation
  • Amneal Pharmaceuticals LLC
  • Abbott Laboratories
  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Limited
  • Zydus Lifesciences Limited
Product Code: A12669

The motion sickness treatment market size valued for $393.70 million in 2021 and is estimated to reach $525.03 million by 2031, exhibiting a CAGR of 2.9% from 2022 to 2031. Motion sickness, also known as travel sickness or kinetosis, is a condition characterized by a set of symptoms that occur when a person is exposed to motion or movement. It occurs when there is a discrepancy between the sensory information that the eyes, inner ear, and body provide to the brain. The brain receives conflicting information from the eyes and inner ear about the movement and orientation of the body, and this can cause a variety of symptoms such as nausea, vomiting, dizziness, headaches, sweating, and fatigue. It can be caused by various forms of motion, including car rides, airplane flights, boat rides, or even virtual reality experiences.

Motion Sickness Treatment Market - IMG1

Motion sickness is more likely to occur in people more prone to it, such as children, pregnant women, and people with a history of migraines. Treatment for motion sickness may include over-the-counter and prescription medications which includes antihistamines, anticholinergics and other medications. The products are available in branded as well as generic form and can be easily accessed through retail and other pharmacies.Major factors that drive the growth of the motion sickness treatment market include increase in incidences of motion sickness, and rise in awareness among the people regarding motion sickness and its treatment options.

In addition, increase in number of travelers is also a major factor contributing toward the market growth. For instance, the World Tourism Organization (UNWTO) stated that more than 900 million tourists travelled internationally in 2022 which was double the number recorded in 2021. This shows a significant increase in the number of travelers, both domestically and internationally. In addition, an article, Motion Sickness: Manifestations and Prevention published by Defence Food Research Laboratory, Mysore stated that, about 5 to 10% of travelers are highly susceptible to motion sickness, while others are moderately susceptible. Thus, it highlights huge incidences of motion sickness among the travelers around the globe, which furthers propels the growth of the motion sickness treatment market.

In addition, major key players are focusing on developing new drugs and APIs that are highly potent and efficient in reducing the symptoms of motion sickness. Moreover, there is an increase in outsourcing research activities by the pharmaceutical companies to private contract research organizations (CROs), which allows the company to stay competitive and flexible in a world of increasingly advanced technologies. This supports the key market players to develop novel drug and medications for motion sickness prevention and treatment, which further propels the growth of the market.

On the other hand, lack of awareness about motion sickness and its available treatment in some underdeveloped countries hinder the growth of the market. In addition, some people may be hesitant to use medication to treat motion sickness due to concerns about side effects or a preference for natural remedies. This is projected to limit the demand for motion sickness medications. Moreover, the presence of alternate solutions, such as wearable, for motion sickness may indeed be a hindrance to the market growth. Wearable devices, such as acupressure bands, wristbands, and headsets, have become increasingly popular in recent years as non-pharmaceutical alternatives for managing motion sickness. These factors limit the growth of the market.

However, emerging economies of Asia-Pacific and LAMEA present lucrative opportunities for market players for investments. These regions are characterized by large populations with high levels of economic growth and increasing disposable incomes. As a result, there is a growing demand for healthcare services, raising awareness for motion sickness treatment medication. Moreover, governments in these regions are increasingly investing in healthcare infrastructure and expanding access to healthcare services, which is further anticipated to augment the market growth.

The motion sickness treatment market is segmented into drug class, route of administration, distribution channel and region. By drugs class, the market is categorized into antihistamines, anticholinergics and others. By route of administration, the market is bifurcated into oral, and others. By distribution channel, the market is segregated into hospital pharmacies, drug stores & retail pharmacies and online pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the motion sickness treatment market include: Prestige Consumer Healthcare Inc., Baxter International Inc., Novartis AG, WellSpring Pharmaceutical Corporation., Amneal Pharmaceuticals LLC., Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Viatris Inc., Zydus Cadila and Teva Pharmaceutical Industries Limited.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the motion sickness treatment market analysis from 2021 to 2031 to identify the prevailing motion sickness treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the motion sickness treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global motion sickness treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

  • Antihistamines
  • Anticholinergics
  • Others

By Route of Administration

  • Oral
  • Others

By Distribution Channel

  • Drug Store and Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

  • Sun Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Limited
  • Prestige Consumer Healthcare Inc.
  • Baxter International Inc.
  • Novartis AG
  • Amneal Pharmaceuticals LLC
  • Abbott Laboratories
  • WellSpring Pharmaceutical Corporation
  • Zydus Lifesciences Limited

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increasing incidence of motion sickness
      • 3.4.1.2. Surge in adoption of motion sickness treatments
      • 3.4.1.3. Surge in product approval and product launches by the key players
    • 3.4.2. Restraints
      • 3.4.2.1. Presence of alternate solution for motion sickness treatment
      • 3.4.2.2. Limited awareness and knowledge about motion sickness
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunity in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Antihistamines
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Anticholinergics
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Oral
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Others
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Store and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Pharmacies
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: MOTION SICKNESS TREATMENT MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drug Class
    • 7.2.3. Market size and forecast, by Route of Administration
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drug Class
      • 7.2.5.1.3. Market size and forecast, by Route of Administration
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drug Class
      • 7.2.5.2.3. Market size and forecast, by Route of Administration
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drug Class
      • 7.2.5.3.3. Market size and forecast, by Route of Administration
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drug Class
    • 7.3.3. Market size and forecast, by Route of Administration
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drug Class
      • 7.3.5.1.3. Market size and forecast, by Route of Administration
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drug Class
      • 7.3.5.2.3. Market size and forecast, by Route of Administration
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drug Class
      • 7.3.5.3.3. Market size and forecast, by Route of Administration
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drug Class
      • 7.3.5.4.3. Market size and forecast, by Route of Administration
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drug Class
      • 7.3.5.5.3. Market size and forecast, by Route of Administration
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drug Class
      • 7.3.5.6.3. Market size and forecast, by Route of Administration
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drug Class
    • 7.4.3. Market size and forecast, by Route of Administration
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drug Class
      • 7.4.5.1.3. Market size and forecast, by Route of Administration
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drug Class
      • 7.4.5.2.3. Market size and forecast, by Route of Administration
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drug Class
      • 7.4.5.3.3. Market size and forecast, by Route of Administration
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drug Class
      • 7.4.5.4.3. Market size and forecast, by Route of Administration
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drug Class
      • 7.4.5.5.3. Market size and forecast, by Route of Administration
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drug Class
      • 7.4.5.6.3. Market size and forecast, by Route of Administration
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drug Class
    • 7.5.3. Market size and forecast, by Route of Administration
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drug Class
      • 7.5.5.1.3. Market size and forecast, by Route of Administration
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drug Class
      • 7.5.5.2.3. Market size and forecast, by Route of Administration
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Drug Class
      • 7.5.5.3.3. Market size and forecast, by Route of Administration
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Drug Class
      • 7.5.5.4.3. Market size and forecast, by Route of Administration
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Prestige Consumer Healthcare Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Baxter International Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
  • 9.3. Novartis AG
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. WellSpring Pharmaceutical Corporation
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
  • 9.5. Amneal Pharmaceuticals LLC
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Abbott Laboratories
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Sun Pharmaceutical Industries Ltd.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Viatris Inc.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Teva Pharmaceutical Industries Limited
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Zydus Lifesciences Limited
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 02. MOTION SICKNESS TREATMENT MARKET FOR ANTIHISTAMINES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. MOTION SICKNESS TREATMENT MARKET FOR ANTICHOLINERGICS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. MOTION SICKNESS TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 05. GLOBAL MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 06. MOTION SICKNESS TREATMENT MARKET FOR ORAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 07. MOTION SICKNESS TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 08. GLOBAL MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 09. MOTION SICKNESS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. MOTION SICKNESS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 11. MOTION SICKNESS TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. MOTION SICKNESS TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. NORTH AMERICA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 14. NORTH AMERICA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 15. NORTH AMERICA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 16. NORTH AMERICA MOTION SICKNESS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. U.S. MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 18. U.S. MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 19. U.S. MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 20. CANADA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 21. CANADA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 22. CANADA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 23. MEXICO MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 24. MEXICO MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 25. MEXICO MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 26. EUROPE MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 27. EUROPE MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 28. EUROPE MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 29. EUROPE MOTION SICKNESS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 30. GERMANY MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 31. GERMANY MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 32. GERMANY MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 33. FRANCE MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 34. FRANCE MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 35. FRANCE MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 36. UK MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 37. UK MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 38. UK MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 39. ITALY MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 40. ITALY MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 41. ITALY MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 42. SPAIN MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 43. SPAIN MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 44. SPAIN MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 45. REST OF EUROPE MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 46. REST OF EUROPE MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 47. REST OF EUROPE MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 48. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 49. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 50. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 51. ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 52. JAPAN MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 53. JAPAN MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 54. JAPAN MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 55. CHINA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 56. CHINA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 57. CHINA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 58. INDIA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 59. INDIA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 60. INDIA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 61. AUSTRALIA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 62. AUSTRALIA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 63. AUSTRALIA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 64. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 65. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 66. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 70. LAMEA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 71. LAMEA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 72. LAMEA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 73. LAMEA MOTION SICKNESS TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 74. BRAZIL MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 75. BRAZIL MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 76. BRAZIL MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 77. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 78. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 79. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 80. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 81. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 83. REST OF LAMEA MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 84. REST OF LAMEA MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 85. REST OF LAMEA MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 86. PRESTIGE CONSUMER HEALTHCARE INC.: KEY EXECUTIVES
  • TABLE 87. PRESTIGE CONSUMER HEALTHCARE INC.: COMPANY SNAPSHOT
  • TABLE 88. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT SEGMENTS
  • TABLE 89. PRESTIGE CONSUMER HEALTHCARE INC.: PRODUCT PORTFOLIO
  • TABLE 90. BAXTER INTERNATIONAL INC.: KEY EXECUTIVES
  • TABLE 91. BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
  • TABLE 92. BAXTER INTERNATIONAL INC.: PRODUCT SEGMENTS
  • TABLE 93. BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
  • TABLE 94. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 95. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 96. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 97. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 98. WELLSPRING PHARMACEUTICAL CORPORATION: KEY EXECUTIVES
  • TABLE 99. WELLSPRING PHARMACEUTICAL CORPORATION: COMPANY SNAPSHOT
  • TABLE 100. WELLSPRING PHARMACEUTICAL CORPORATION: PRODUCT SEGMENTS
  • TABLE 101. WELLSPRING PHARMACEUTICAL CORPORATION: PRODUCT PORTFOLIO
  • TABLE 102. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 103. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 104. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
  • TABLE 105. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 106. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 107. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 108. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 109. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 110. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 111. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 114. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 115. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 116. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 117. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 118. VIATRIS INC.: KEY STRATERGIES
  • TABLE 119. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
  • TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
  • TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
  • TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
  • TABLE 123. ZYDUS LIFESCIENCES LIMITED: KEY EXECUTIVES
  • TABLE 124. ZYDUS LIFESCIENCES LIMITED: COMPANY SNAPSHOT
  • TABLE 125. ZYDUS LIFESCIENCES LIMITED: PRODUCT SEGMENTS
  • TABLE 126. ZYDUS LIFESCIENCES LIMITED: PRODUCT PORTFOLIO
  • TABLE 127. ZYDUS LIFESCIENCES LIMITED: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. MOTION SICKNESS TREATMENT MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF MOTION SICKNESS TREATMENT MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN MOTION SICKNESS TREATMENT MARKET (2022-2031)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALMOTION SICKNESS TREATMENT MARKET
  • FIGURE 10. MOTION SICKNESS TREATMENT MARKET, BY DRUG CLASS, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TREATMENT MARKET FOR ANTIHISTAMINES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TREATMENT MARKET FOR ANTICHOLINERGICS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TREATMENT MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 14. MOTION SICKNESS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TREATMENT MARKET FOR ORAL, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TREATMENT MARKET FOR OTHERS, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 17. MOTION SICKNESS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TREATMENT MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF MOTION SICKNESS TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY 2021 AND 2031(%)
  • FIGURE 21. MOTION SICKNESS TREATMENT MARKET BY REGION, 2021
  • FIGURE 22. U.S. MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 23. CANADA MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 24. MEXICO MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. GERMANY MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. FRANCE MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. UK MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. ITALY MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. SPAIN MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. REST OF EUROPE MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. JAPAN MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. CHINA MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. INDIA MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. AUSTRALIA MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. SOUTH KOREA MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. REST OF ASIA-PACIFIC MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. BRAZIL MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. SAUDI ARABIA MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. SOUTH AFRICA MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. REST OF LAMEA MOTION SICKNESS TREATMENT MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45. COMPETITIVE DASHBOARD
  • FIGURE 46. COMPETITIVE HEATMAP: MOTION SICKNESS TREATMENT MARKET
  • FIGURE 47. TOP PLAYER POSITIONING, 2021
  • FIGURE 48. PRESTIGE CONSUMER HEALTHCARE INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 49. PRESTIGE CONSUMER HEALTHCARE INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 50. PRESTIGE CONSUMER HEALTHCARE INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 51. BAXTER INTERNATIONAL INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 52. BAXTER INTERNATIONAL INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 53. BAXTER INTERNATIONAL INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 54. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 55. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 56. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 57. AMNEAL PHARMACEUTICALS LLC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 58. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 60. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 61. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 62. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 63. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 64. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 65. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 66. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 67. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 68. ZYDUS LIFESCIENCES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 69. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 70. ZYDUS LIFESCIENCES LIMITED: REVENUE SHARE BY REGION, 2022 (%)